Dr. Florin Rader reviews the results of treatment with mavacamten from the EXPLORER-LTE cohort of the MAVA-LTE study in patients with obstructive hypertrophic cardiomyopathy (HCM).
Reductions in LVOT Gradients, NYHA Class, & NT-proBNP with Cardiac Myosin Inhibitor in HCM

Transcript
Reductions in LVOT Gradients, NYHA Class, & NT-proBNP with Cardiac Myosin Inhibitor in HCM
closeReady to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Dr. Florin Rader reviews the results of treatment with mavacamten from the EXPLORER-LTE cohort of the MAVA-LTE study in patients with obstructive hypertrophic cardiomyopathy (HCM).
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Bridging Distances in PAH: Bringing Best Practices to the People Through Telementoring
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
Partnering with Patients: Building Effective Communication and Support in HF Care
A Practical Guide to Prescribing in HF
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?